US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

YieldMax MRNA Option Income Strategy ETF

34.42

+2.427.56%

Post-market: 34.33-0.0949-0.28%19:57 EDT

Volume:560.47K

Turnover:19.49M

Market Cap:219.60M

PE:- -

High:37.50

Open:31.89

Low:31.89

Close:32.00

52wk High:42.39

52wk Low:13.60

Shares:6.38M

Float Shares:6.38M

Volume Ratio:0.45

T/O Rate:8.78%

Dividend:14.34

Dividend Rate:41.66%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Moderna: Gets U.S. FDA Approval for Influenza Vaccine Mflusiva for Use in Adults 50 Years and Older

THOMSON REUTERS

Moderna: Expects Supply of Influenza Vaccine Mflusiva to be Available in Select Retailers in Coming Weeks

THOMSON REUTERS

Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1

Moderna Shingles Vaccine Trial Terminated: What It Means for MRNA Investors

Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine

Moderna announces initiation of Phase 1 trial of mRNA-1469

Moderna Publishes Transcript of Q2 2026 Earnings Call

Moderna: Mrna-1469 Phase 1 Trial Conducted in Canada as Part of Expanded Collaboration with Coalition for Epidemic Preparedness Innovations

THOMSON REUTERS

Moderna: Under Cepi Agreement, Commits Minimum 500,000 Doses of Mrna-1469 Vaccine for Low- and Middle-Income Countries Under Access Pricing

THOMSON REUTERS

Moderna: Mrna-1469 Phase 1 Trial to Evaluate Safety & Immune Response for Bundibugyo Ebolavirus

THOMSON REUTERS

J.P. Morgan Remains a Sell on Moderna (MRNA)

Fresenius announces FDA approval of rituximab biosimilar

Moderna is Maintained at Neutral by Citigroup

Moderna Facing Several Vaccine Headwinds in Near, Medium Term, RBC Says

MT Newswires Live

UBS Raises Moderna Price Target to $50 From $45, Maintains Neutral Rating

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Moderna (MRNA) and Stevanato Group (STVN)

Moderna : Bofa Global Research Raises Price Objective to $40 from $38

THOMSON REUTERS

Ocular Therapeutix Q2 Product Revenue Flat, Net Loss Widens on Higher Spending

TG Therapeutics Q2 Product Revenue Rises 70% on Briumvi Sales

Krystal Biotech Q2 Revenue Rises on Vyjuvek Strength

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/MRNY/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MRNY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MRNY\",,,,,undefined,":{"symbol":"MRNY","market":"US","secType":"STK","nameCN":"YieldMax MRNA Option Income Strategy ETF","latestPrice":34.42,"timestamp":1787342400000,"preClose":32,"halted":0,"volume":560470,"hourTrading":{"tag":"盘后","latestPrice":34.3251,"preClose":34.42,"latestTime":"19:57 EDT","volume":4781,"amount":164670.2229,"timestamp":1787356626729,"change":-0.0949,"changeRate":-0.002757,"amplitude":0.018446},"delay":0,"changeRate":0.07562500000000005,"floatShares":6380000,"shares":6380000,"eps":0,"marketStatus":"Market Closed","change":2.42,"latestTime":"08-21 16:00:00 EDT","open":31.89,"high":37.5,"low":31.89,"amount":19487401.782500003,"amplitude":0.175312,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":32,"sharesOutstanding":6479974,"nav":31.95,"aum":142336419.3,"dividendRate":0.416638,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":31.8,"preClose":32,"latestTime":"09:29 EDT","volume":8147,"amount":265000.89074,"timestamp":1787318983976,"change":-0.2,"changeRate":-0.00625,"amplitude":0.10875},"postHourTrading":{"tag":"盘后","latestPrice":34.3251,"preClose":34.42,"latestTime":"19:57 EDT","volume":4781,"amount":164670.2229,"timestamp":1787356626729,"change":-0.0949,"changeRate":-0.002757,"amplitude":0.018446},"volumeRatio":0.4523323520535589,"impliedVol":0.845,"impliedVolPercentile":0.812},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MRNY\",,,,,undefined,":{"symbol":"MRNY","floatShares":6380000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.4523323520535589,"shares":6380000,"dividePrice":14.340667,"high":37.5,"amplitude":0.175312,"preClose":32,"low":31.89,"week52Low":13.6,"pbRate":"--","week52High":42.39,"institutionHeld":0,"latestPrice":34.42,"eps":0,"divideRate":0.416638,"volume":560470,"delay":0,"ttmEps":0,"open":31.89,"prevYearClose":14.7,"prevWeekClose":15.68,"prevMonthClose":14.4,"prevQuarterClose":19.33,"fiveDayClose":15.68,"twentyDayClose":14.36,"sixtyDayClose":15.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MRNY\",params:#limit:5,,,undefined,":[{"date":"2026-08-20","symbol":"MRNY","amount":0.2261,"announcedDate":"2026-08-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-20","defaultRemindTime":1787232600000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-21","payableDate":"2026-08-20","currency":"USD","dateTimestamp":1787198400000,"payDate":"2026-08-21"},{"date":"2026-08-13","symbol":"MRNY","amount":0.2216,"announcedDate":"2026-08-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-13","defaultRemindTime":1786627800000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-14","payableDate":"2026-08-13","currency":"USD","dateTimestamp":1786593600000,"payDate":"2026-08-14"},{"date":"2026-08-06","symbol":"MRNY","amount":0.2038,"announcedDate":"2026-08-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-06","defaultRemindTime":1786023000000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-07","payableDate":"2026-08-06","currency":"USD","dateTimestamp":1785988800000,"payDate":"2026-08-07"},{"date":"2026-07-30","symbol":"MRNY","amount":0.2374,"announcedDate":"2026-07-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-30","defaultRemindTime":1785418200000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-31","payableDate":"2026-07-30","currency":"USD","dateTimestamp":1785384000000,"payDate":"2026-07-31"},{"date":"2026-07-23","symbol":"MRNY","amount":0.2524,"announcedDate":"2026-07-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-07-23","defaultRemindTime":1784813400000,"name":"MRNA期权收益策略ETF-YieldMax","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-07-24","payableDate":"2026-07-23","currency":"USD","dateTimestamp":1784779200000,"payDate":"2026-07-24"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MRNY\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-07","recordDate":"2023-12-08","paymentDate":"2023-12-13","value":0.413,"currency":"USD"},{"executeDate":"2024-01-05","recordDate":"2024-01-08","paymentDate":"2024-01-09","value":2.6542,"currency":"USD"},{"executeDate":"2024-02-07","recordDate":"2024-02-08","paymentDate":"2024-02-09","value":0.5944,"currency":"USD"},{"executeDate":"2024-03-06","recordDate":"2024-03-07","paymentDate":"2024-03-08","value":1.131,"currency":"USD"},{"executeDate":"2024-04-04","recordDate":"2024-04-05","paymentDate":"2024-04-08","value":0.7832,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MRNY\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MRNY\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657503984","title":"Moderna: Gets U.S. FDA Approval for Influenza Vaccine Mflusiva for Use in Adults 50 Years and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=2657503984","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657503984?lang=en_us&edition=fundamental","pubTime":"2026-08-06 10:15","pubTimestamp":1785982558,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nP8N4010G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4501","IDNA","MRNY","GNOM","BK4551","BK4534","BK4533","BK4568","BK4532","LGHT","WDNA","BK4585","MRNX","BK4139","MRNA","BK4548","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657039825","title":"Moderna: Expects Supply of Influenza Vaccine Mflusiva to be Available in Select Retailers in Coming Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2657039825","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657039825?lang=en_us&edition=fundamental","pubTime":"2026-08-06 10:15","pubTimestamp":1785982558,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nP8N4010G0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4551","BK4534","BK4568","BK4548","BK4139","BK4585","MRNX","BK4588","IDNA","MRNA","LGHT","GNOM","BK4533","MRNY","BK4501","WDNA","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572786","title":"Takeda Wins First-in-Class U.S. Approval for Orexin Therapy in Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572786","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572786?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:25","pubTimestamp":1785972320,"startTime":"0","endTime":"0","summary":"The latest update is out from Takeda Pharmaceutical Co ( ($JP:4502) ). Takeda has secured U.S. FDA approval for ORZEYFUL, an oral orexin receptor 2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/takeda-wins-first-in-class-u-s-approval-for-orexin-therapy-in-narcolepsy-type-1?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","TBXU","MRNY","LABU","GDOC","PSCH","RSPH","IDNA","TECB","IBB","BK4585","SYNB","BBP","GNMX","IYH","MRNX","PINK","LFSC","FRTY","BK4588","BMED","NVIB","XLVX","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657608529","title":"Moderna Shingles Vaccine Trial Terminated: What It Means for MRNA Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2657608529","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657608529?lang=en_us&edition=fundamental","pubTime":"2026-08-06 00:30","pubTimestamp":1785947438,"startTime":"0","endTime":"0","summary":"Moderna ($MRNA) announced an update on their ongoing clinical study. Moderna (MRNA) has halted a key early study of mRNA-1468, its experimental shi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/moderna-shingles-vaccine-trial-terminated-what-it-means-for-mrna-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/moderna-shingles-vaccine-trial-terminated-what-it-means-for-mrna-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4533","BK4551","BK4585","BK4548","BK4211","BK4534","MRNX","BK4568","LGHT","ISBC","IDNA","WDNA","MRNA","GNOM","BK4588","MRNY","BK4501","BK4139","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657568591","title":"Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine","url":"https://stock-news.laohu8.com/highlight/detail?id=2657568591","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657568591?lang=en_us&edition=fundamental","pubTime":"2026-08-05 00:36","pubTimestamp":1785861360,"startTime":"0","endTime":"0","summary":"Moderna shares got a boost after the drugmaker said it had vaccinated the first participants in an early-stage clinical trial evaluating the safety of its Ebola vaccine candidate, mRNA-1469.Conducted ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Moderna Stock Jumps on Trial Launch for Breakthrough Ebola Vaccine","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","WDNA","GNOM","BK4501","IDNA","BK4533","BK4532","BK4568","MRNX","MRNY","BK4139","BK4534","MRNA","LGHT","BK4588","BK4548","BK4551"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656557491","title":"Moderna announces initiation of Phase 1 trial of mRNA-1469","url":"https://stock-news.laohu8.com/highlight/detail?id=2656557491","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656557491?lang=en_us&edition=fundamental","pubTime":"2026-08-04 23:05","pubTimestamp":1785855923,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) announced that following Health Canada’s authorization of the study, the first participants have been vaccinated in a Phase 1 clinic...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moderna-announces-initiation-of-phase-1-trial-of-mrna-1469-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moderna-announces-initiation-of-phase-1-trial-of-mrna-1469-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","GNOM","BK4585","BK4534","IDNA","BK4501","WDNA","BK4533","BK4551","MRNY","BBC","BK4139","LGHT","MRNA","BK4548","BK4568","BK4532","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656557590","title":"Moderna Publishes Transcript of Q2 2026 Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2656557590","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656557590?lang=en_us&edition=fundamental","pubTime":"2026-08-04 23:00","pubTimestamp":1785855638,"startTime":"0","endTime":"0","summary":"Moderna publishes transcript of Q2 2026 earnings callModerna’s Q2 2026 earnings call featured CEO Stephane Bancel, President Stephen Hoge, CFO James Mock, CDO David Berman, investor relations lead Lav","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL4z8ZPh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","IDNA","MRNY","GNOM","BK4551","BK4534","BK4533","BK4568","BK4532","LGHT","WDNA","BK4585","MRNX","BK4139","MRNA","BK4548","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656573945","title":"Moderna: Mrna-1469 Phase 1 Trial Conducted in Canada as Part of Expanded Collaboration with Coalition for Epidemic Preparedness Innovations","url":"https://stock-news.laohu8.com/highlight/detail?id=2656573945","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656573945?lang=en_us&edition=fundamental","pubTime":"2026-08-04 23:00","pubTimestamp":1785855600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nP8N40P08D:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4501","BK4588","MRNX","BK4139","IDNA","BK4533","BK4534","MRNY","MRNA","WDNA","BK4551","BK4585","GNOM","BK4568","BK4548","LGHT","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656557562","title":"Moderna: Under Cepi Agreement, Commits Minimum 500,000 Doses of Mrna-1469 Vaccine for Low- and Middle-Income Countries Under Access Pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=2656557562","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656557562?lang=en_us&edition=fundamental","pubTime":"2026-08-04 23:00","pubTimestamp":1785855600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nP8N40P08D:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4568","BK4533","MRNA","BK4551","BK4534","MRNY","GNOM","MRNX","LGHT","BK4501","BK4588","WDNA","BK4139","IDNA","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656557391","title":"Moderna: Mrna-1469 Phase 1 Trial to Evaluate Safety & Immune Response for Bundibugyo Ebolavirus","url":"https://stock-news.laohu8.com/highlight/detail?id=2656557391","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656557391?lang=en_us&edition=fundamental","pubTime":"2026-08-04 23:00","pubTimestamp":1785855600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nP8N40P08D:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MRNY","WDNA","BK4532","LGHT","BK4534","BK4588","BK4501","MRNA","BK4533","GNOM","IDNA","MRNX","BK4139","BK4551","BK4585","BK4548","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656874552","title":"J.P. Morgan Remains a Sell on Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656874552","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656874552?lang=en_us&edition=fundamental","pubTime":"2026-08-04 22:21","pubTimestamp":1785853307,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Jessica Fye maintained a Sell rating on Moderna today and set a price target of $40.00. Fye covers the Healthcare sector, focus...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-sell-on-moderna-mrna-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-remains-a-sell-on-moderna-mrna-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KBWB","LU2111349929.HKD","BK4501","IDNA","LU2264538146.SGD","LU1064131342.USD","BK4533","LU1548497426.USD","LU0158827781.USD","BK4551","WDNA","LU1244550577.SGD","BK4534","BK4568","LU1074936037.SGD","LU1363072403.SGD","LU1791710400.SGD","MRNX","LGHT","LU0234570918.USD","LU1732799900.SGD","LU0006306889.USD","LU2271345857.HKD","BK4588","LU1732800096.USD","MRNY","LU1989772923.USD","XBI","LU0225283273.USD","LU2487616109.SGD","LU1720051108.HKD","LU2133065610.SGD","LU0053666078.USD","LU1668664300.SGD","GNOM","IE00BKVL7J92.USD","BK4532","LU1791710582.SGD","MRNA","LABU","XLV","LU0971096721.USD","LU0795875169.SGD","LU1244550221.USD","LU0210528500.USD","BK4127","BK4139","IAI","BK4581","LU2023251221.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656304376","title":"Fresenius announces FDA approval of rituximab biosimilar","url":"https://stock-news.laohu8.com/highlight/detail?id=2656304376","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656304376?lang=en_us&edition=fundamental","pubTime":"2026-08-04 04:15","pubTimestamp":1785788150,"startTime":"0","endTime":"0","summary":"Fresenius Kabi, an operating company of Fresenius (FSNUY), announced that the U.S. Food and Drug Administration has approved a rituximab biosimilar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/fresenius-announces-fda-approval-of-rituximab-biosimilar-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/fresenius-announces-fda-approval-of-rituximab-biosimilar-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLVX","LFSC","GDOC","PINK","IYH","BBP","RSPH","TBXU","NVIB","IDNA","IEIH","BK4196","FRTY","PSCH","TECB","MRNX","BMED","FSNUY","IBB","BK4588","BK4585","GNMX","SYNB","MRNY","LABU","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656062863","title":"Moderna is Maintained at Neutral by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2656062863","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656062863?lang=en_us&edition=fundamental","pubTime":"2026-08-04 02:52","pubTimestamp":1785783120,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MRNA/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4501","BK4534","BK4548","IDNA","GNOM","MRNY","BK4532","MRNA","BK4585","BK4551","MRNX","BK4533","BK4568","WDNA","LGHT","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656330332","title":"Moderna Facing Several Vaccine Headwinds in Near, Medium Term, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2656330332","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656330332?lang=en_us&edition=fundamental","pubTime":"2026-08-04 00:20","pubTimestamp":1785774052,"startTime":"0","endTime":"0","summary":"Moderna  is facing several vaccine headwinds in the near to medium term, particularly for its COVID and respiratory syncytial virus vaccines, RBC Capital Markets said in a note emailed Monday.The company's Q2 results were \"relatively unconventional,\" RBC said, noting that product revenue was generally in line with expectations. Moderna reported a Q2 net loss of $1.97 per diluted share, narrowing from a loss of $2.13 a year earlier, as revenue increased to $145 million from $142 million.Among the highlights of the quarter is Moderna's norovirus vaccine missing the phase 3 interim, RBC said. The company did not issue material updates on individualized neoantigen therapy but a phase 3 study in melanoma remains on track, with potential interim readout within the year, the brokerage added.Meanwhile, the Aug. 5 target action date for Moderna's flu vaccine approaches and is likely to get approved, RBC said.RBC kept its sector perform rating on Moderna, with a $45 per share price target.Price:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4534","BK4548","MRNY","BK4501","LGHT","BK4585","BK4532","GNOM","MRNA","WDNA","BK4139","BK4568","IDNA","BK4533","BK4551","BK4588","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656372700","title":"UBS Raises Moderna Price Target to $50 From $45, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2656372700","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656372700?lang=en_us&edition=fundamental","pubTime":"2026-08-03 22:09","pubTimestamp":1785766153,"startTime":"0","endTime":"0","summary":"Moderna (MRNA) has an average rating of hold and mean price target of $53.79, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4533","MRNX","BK4501","BK4568","MRNA","BK4139","BK4551","BK4585","IDNA","BK4548","WDNA","BK4532","BK4534","LGHT","GNOM","BK4588","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656379084","title":"Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Moderna (MRNA) and Stevanato Group (STVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656379084","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656379084?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:40","pubTimestamp":1785760809,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Ascendis Pharma (ASND), Moderna (MRNA) and Stevana...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-moderna-mrna-and-stevanato-group-stvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-moderna-mrna-and-stevanato-group-stvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNX","ASND","BK4534","BK4532","BK4533","XBI","STVN","BK4581","BK4588","LU0109394709.USD","HCSG","MEDI","BK4501","MRNA","GNOM","IDNA","BK4585","BK4551","LU0128526141.USD","BK4139","LU0029874061.USD","BK4548","LU0889565916.HKD","MRNY","LABU","XLV","BK4539","BK4568","LGHT","BK4121","BK4137","LU0320765992.SGD","WDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656063376","title":"Moderna : Bofa Global Research Raises Price Objective to $40 from $38","url":"https://stock-news.laohu8.com/highlight/detail?id=2656063376","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656063376?lang=en_us&edition=fundamental","pubTime":"2026-08-03 20:14","pubTimestamp":1785759261,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nFWN44014U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","MRNX","BK4588","BK4533","BK4501","BK4139","LGHT","BK4548","BK4568","BK4551","WDNA","GNOM","MRNA","MRNY","IDNA","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656375311","title":"Ocular Therapeutix Q2 Product Revenue Flat, Net Loss Widens on Higher Spending","url":"https://stock-news.laohu8.com/highlight/detail?id=2656375311","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656375311?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:21","pubTimestamp":1785756090,"startTime":"0","endTime":"0","summary":"Ocular Therapeutix Q2 product revenue flat, net loss widens on higher spendingOverviewUS biopharmaceutical firm's Q2 product revenue was flat yr/yrNet loss for Q2 widened compared to prior yearCompany","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400DI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4534","OCUL","TGTX","BK4551","MRNX","BK4588","GNOM","MRNA","KRYS","IDNA","HELX","BK4568","BK4007","PSCH","BK4139","BK4548","MRNY","BK4501","BK4533","LGHT","WDNA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656373720","title":"TG Therapeutics Q2 Product Revenue Rises 70% on Briumvi Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2656373720","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656373720?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:13","pubTimestamp":1785755580,"startTime":"0","endTime":"0","summary":"TG Therapeutics Q2 product revenue rises 70% on BRIUMVI salesOverviewU.S. biotech's Q2 product revenue rose 70% yr/yr, driven by BRIUMVI salesQ2 net income and EPS declined from prior year as expenses","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400D6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4533","BK4007","BK4501","MRNY","TENX","BK4568","WDNA","BK4585","IDNA","BK4139","GNOM","BK4534","BK4532","LGHT","MRNX","MRNA","BK4548","BK4588","BK4551","TGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656373795","title":"Krystal Biotech Q2 Revenue Rises on Vyjuvek Strength","url":"https://stock-news.laohu8.com/highlight/detail?id=2656373795","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656373795?lang=en_us&edition=fundamental","pubTime":"2026-08-03 19:12","pubTimestamp":1785755552,"startTime":"0","endTime":"0","summary":"Krystal Biotech Q2 revenue rises on VYJUVEK strengthOverviewUS genetic medicines developer's Q2 product revenue grew 24% yr/yr to $119.2 mlnAdjusted EPS for Q2 rose to $1.79 from $1.29 a year agoCompa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nL1N4400D3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","IE00BGHQF631.EUR","MRNA","FHLC","GNOM","LU1934455863.HKD","LU0511384066.AUD","MRNY","LGHT","GLAM","BK4581","IXJ","LU2089283258.USD","HELX","PSCH","AGNG","PPH","LU0234572021.USD","LU1244550221.USD","IE0002270589.USD","TRUH","LU1732799900.SGD","LU2237443622.USD","LU2237443465.HKD","RXL","LU0553294199.USD","FTXH","KRYS","LU2357627491.SGD","MRNX","IE00BVYPNW00.USD","ABBV","LU0859254822.USD","LU1923622614.USD","IYH","VHT","XLV","LU0456855351.SGD","IE00BLSP4239.USD","LU0320765646.SGD","LU2089284900.SGD","JDOC","MEDX","LU2129689514.USD","PJP","SG9999015945.SGD","IDNA","LU1061106388.HKD","WDNA","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}